https://www.parisdailyreporter.com/article/907567405-american-management-university-expands-access-to-learning-through-60-free-e-certificate-programs-available-worldwide Paris Daily Reporter en PressRelease 2026-04-23T18:03:11+00:00 American Management University Expands Access to Learning Through 60+ Free E-Certificate Programs Available Worldwide https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/5494719-wall-mock-up-4000x2667.jpeg https://www.parisdailyreporter.com/article/907521066-les-produits-de-la-mer-britanniques-mettent-en-avant-leurs-atouts-au-seafood-expo-global Paris Daily Reporter en PressRelease 2026-04-23T14:40:43+00:00 Les produits de la mer britanniques mettent en avant leurs atouts au Seafood Expo Global https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24839372-seaf1-1096x730.jpeg https://www.parisdailyreporter.com/article/907333521-vera-co-founder-julie-cropp-gareleck-featured-as-a-leading-voice-on-people-first-ai-and-workforce-transformation Paris Daily Reporter en PressRelease 2026-04-23T10:00:00+00:00 Vera Co-Founder Julie Cropp Gareleck Featured as a Leading Voice on People-First AI and Workforce Transformation https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/23803362-vera-corporate-company-logo-3333x2500.jpeg https://www.parisdailyreporter.com/article/907567508-vantiva-first-quarter-2026-sales-and-refinancing Paris Daily Reporter en PressRelease 2026-04-23T17:03:00+00:00 Vantiva - First Quarter 2026 Sales and Refinancing https://ml-eu.globenewswire.com/media/a1774cf2-0a53-4c3c-8c80-6dff1dff7bd3/small/vantiva-logo-with-tagline-512x384-1-png.png https://www.parisdailyreporter.com/article/907567539-vantiva-chiffre-d-affaires-du-premier-trimestre-et-refinancement Paris Daily Reporter en PressRelease 2026-04-23T17:03:00+00:00 Vantiva - Chiffre d’affaires du premier trimestre et refinancement https://ml-eu.globenewswire.com/media/a1774cf2-0a53-4c3c-8c80-6dff1dff7bd3/small/vantiva-logo-with-tagline-512x384-1-png.png https://www.parisdailyreporter.com/article/907567352-vantiva-results-full-year-2025 Paris Daily Reporter en PressRelease 2026-04-23T17:00:00+00:00 Vantiva - Results Full Year 2025 https://ml-eu.globenewswire.com/media/a1774cf2-0a53-4c3c-8c80-6dff1dff7bd3/small/vantiva-logo-with-tagline-512x384-1-png.png https://www.parisdailyreporter.com/article/907567440-vantiva-r-sultats-annuels-2025 Paris Daily Reporter en PressRelease 2026-04-23T17:00:00+00:00 Vantiva - Résultats annuels 2025 https://ml-eu.globenewswire.com/media/a1774cf2-0a53-4c3c-8c80-6dff1dff7bd3/small/vantiva-logo-with-tagline-512x384-1-png.png https://www.parisdailyreporter.com/article/907567137-alliance-developpement-capital-siic-communiqu-sur-les-r-sultats-au-31-d-cembre-2025 Paris Daily Reporter en PressRelease 2026-04-23T16:17:43+00:00 ALLIANCE DEVELOPPEMENT CAPITAL SIIC: Communiqué sur les résultats au 31 décembre 2025 https://ml-eu.globenewswire.com/media/8664cbf6-d86b-47c0-a845-52067ee079be/small/ https://www.parisdailyreporter.com/article/907566642-chiffre-d-affaires-du-1er-trimestre-2026 Paris Daily Reporter en PressRelease 2026-04-23T15:45:00+00:00 Chiffre d’affaires du 1er trimestre 2026 https://ml-eu.globenewswire.com/media/c4731c25-21f2-47d1-910e-edbaeb4de604/small/ https://www.parisdailyreporter.com/article/907566874-q1-2026-revenue Paris Daily Reporter en PressRelease 2026-04-23T15:45:00+00:00 Q1 2026 revenue https://ml-eu.globenewswire.com/media/c4731c25-21f2-47d1-910e-edbaeb4de604/small/logo-color-cmjn-bd-jpg.jpg https://www.parisdailyreporter.com/article/907549770-blacknut-levels-up-select-activision-publishing-and-blizzard-entertainment-games-now-streamable-on-blacknut Paris Daily Reporter en PressRelease 2026-04-23T15:15:00+00:00 Blacknut Levels Up: Select Activision Publishing and Blizzard Entertainment Games Now Streamable on Blacknut https://ml.globenewswire.com/media/ZWU5OWVkMGEtZWFlZC00MTc5LTlkZjItYzc1MjBhZmQwMDdkLTEyNTc1NzEtMjAyNi0wNC0yMy1lbg==/tiny/Blacknut.png https://www.parisdailyreporter.com/article/907538436-oriental-jewelry-shine-by-the-seine-china-s-pearl-hub-zhuji-promotes-city-industry-in-paris Paris Daily Reporter en PressRelease 2026-04-23T13:00:00+00:00 Oriental Jewelry Shine by the Seine: China's Pearl Hub Zhuji Promotes City, Industry in Paris https://ml.globenewswire.com/media/MjQ1NGI3OGUtNGRhYS00MzM0LTlkYWEtNzhlYWI1ODY1ODU4LTUwMDE2MTU1OC0yMDI2LTA0LTIzLWVu/tiny/Zhejiang-Pearl-Industry-Associ.png https://www.parisdailyreporter.com/article/907490040-last-patient-last-visit-completed-in-phase-i-clinical-trial-of-pulsesight-therapeutics-pst-611-treatment-for-dry-amd-geographic-atrophy-ga Paris Daily Reporter en PressRelease 2026-04-23T07:00:00+00:00 Last patient, last visit completed in Phase I clinical trial of PulseSight Therapeutics’ PST-611 treatment for dry AMD/Geographic Atrophy (GA) https://ml-eu.globenewswire.com/media/9f8ee53c-2465-4c3c-870e-4077c6a39edb/small/pulsesight-therapeutics-logo-horizontal-full-gradient-mark-0.png https://www.parisdailyreporter.com/article/907472537-ose-immunotherapeutics-annonce-la-pr-sentation-des-r-sultats-de-l-tude-de-phase-2-tedova-de-tedopi-dans-le-cancer-de-l-ovaire-au-congr-s-2026-de Paris Daily Reporter en PressRelease 2026-04-23T05:30:00+00:00 OSE Immunotherapeutics annonce la présentation des résultats de l'étude de Phase 2 TEDOVA de Tedopi® dans le cancer de l’ovaire au Congrès 2026 de l’ASCO https://ml-eu.globenewswire.com/media/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22/small/ https://www.parisdailyreporter.com/article/907472704-communiqu-de-presse-t1-2026-croissance-deux-chiffres-du-chiffre-d-affaires-et-du-bnpa Paris Daily Reporter en PressRelease 2026-04-23T05:30:00+00:00 Communiqué de presse : T1 2026 : croissance à deux chiffres du chiffre d’affaires et du BNPA https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://www.parisdailyreporter.com/article/907472829-ose-immunotherapeutics-announces-presentation-of-tedova-phase-2-topline-results-of-tedopi-in-ovarian-cancer-at-the-asco-2026-meeting Paris Daily Reporter en PressRelease 2026-04-23T05:30:00+00:00 OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting https://ml-eu.globenewswire.com/media/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22/small/ose-logo-horizontal-rvb-png.png https://www.parisdailyreporter.com/article/907472887-eramet-strong-turnover-momentum-in-q1-2026-driven-by-a-solid-operational-performance Paris Daily Reporter en PressRelease 2026-04-23T05:30:00+00:00 Eramet: strong turnover momentum in Q1 2026 driven by a solid operational performance https://ml-eu.globenewswire.com/media/39e0e6de-e61c-466c-8714-84980b493551/small/logo-jpg.jpg https://www.parisdailyreporter.com/article/907472891-eramet-croissance-soutenue-du-chiffre-d-affaires-au-1er-trimestre-2026-port-e-par-une-bonne-performance-op-rationnelle Paris Daily Reporter en PressRelease 2026-04-23T05:30:00+00:00 Eramet : croissance soutenue du chiffre d’affaires au 1er trimestre 2026 portée par une bonne performance opérationnelle https://ml-eu.globenewswire.com/media/39e0e6de-e61c-466c-8714-84980b493551/small/ https://www.parisdailyreporter.com/article/907473075-press-release-q1-2026-double-digit-sales-and-business-eps-growth Paris Daily Reporter en PressRelease 2026-04-23T05:30:00+00:00 Press Release: Q1 2026: double-digit sales and business EPS growth https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://www.parisdailyreporter.com/article/907473115-ipsen-delivers-strong-sales-in-the-first-quarter-of-2026-and-confirms-its-full-year-guidance Paris Daily Reporter en PressRelease 2026-04-23T05:00:00+00:00 Ipsen delivers strong sales in the first quarter of 2026 and confirms its full-year guidance https://ml-eu.globenewswire.com/media/81292fcc-6b3a-4e4a-a083-ea4191bf920a/small/ipsen-notified-website-1200x628pix-500kb-max-jpg.jpg https://www.parisdailyreporter.com/article/907473136-ipsen-enregistre-une-forte-croissance-de-ses-ventes-au-premier-trimestre-2026-et-confirme-ses-objectifs-annuels Paris Daily Reporter en PressRelease 2026-04-23T05:00:00+00:00 Ipsen enregistre une forte croissance de ses ventes au premier trimestre 2026 et confirme ses objectifs annuels https://ml-eu.globenewswire.com/media/81292fcc-6b3a-4e4a-a083-ea4191bf920a/small/ https://www.parisdailyreporter.com/article/907294682-altimetrik-partners-with-google-cloud-to-scale-enterprise-ai Paris Daily Reporter en PressRelease 2026-04-22T12:30:00+00:00 Altimetrik Partners with Google Cloud to Scale Enterprise AI https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24838194-raj-sundaresan-1600x2400.jpeg https://www.parisdailyreporter.com/article/906858101-thai-union-group-joins-protecting-blue-whales-blue-skies-to-advance-more-responsible-shipping-on-california-coast Paris Daily Reporter en PressRelease 2026-04-22T12:00:00+00:00 Thai Union Group Joins Protecting Blue Whales & Blue Skies to Advance More Responsible Shipping on California Coast https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24836812-thai-union-x-bwbs-2048x1365.png https://www.parisdailyreporter.com/article/906911459-istituto-marangoni-milano-design-wins-the-fendi-design-prize-2026-and-presents-design-awakens-at-milan-design-week Paris Daily Reporter en PressRelease 2026-04-22T11:46:21+00:00 ISTITUTO MARANGONI MILANO DESIGN WINS THE FENDI DESIGN PRIZE 2026 AND PRESENTS 'DESIGN AWAKENS' AT MILAN DESIGN WEEK https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24837418-alessi-istituto-marangoni-mila-1575x1182.jpeg https://www.parisdailyreporter.com/article/907404570-press-release-sanofi-and-regeneron-s-dupixent-approved-in-the-us-as-the-first-biologic-medicine-for-young-children-with-uncontrolled-chronic Paris Daily Reporter en PressRelease 2026-04-22T21:30:00+00:00 Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://www.parisdailyreporter.com/article/907404644-communiqu-de-presse-dupixent-d-velopp-par-sanofi-et-regeneron-a-t-approuv-aux-tats-unis-comme-tant-le-premier-m-dicament-biologique-pour Paris Daily Reporter en PressRelease 2026-04-22T21:30:00+00:00 Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé aux États-Unis comme étant le premier médicament biologique pour les jeunes enfants atteints d’urticaire chronique spontanée non contrôlée https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://www.parisdailyreporter.com/article/907293893-nudie-jeans-s-attaque-la-fast-fashion-avec-l-ouverture-d-un-store-dans-le-marais-le-23-avril Paris Daily Reporter en PressRelease 2026-04-22T09:07:36+00:00 Nudie Jeans s’attaque à la fast fashion avec l’ouverture d’un store dans le Marais le 23 avril https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24838183-nudie-jeans-le-marais-1448x1086.png https://www.parisdailyreporter.com/article/907389412-abivax-to-present-data-on-obefazimod-at-digestive-disease-week Paris Daily Reporter en PressRelease 2026-04-22T20:05:00+00:00 Abivax to Present Data on Obefazimod at Digestive Disease Week® https://ml-eu.globenewswire.com/media/5470cd7e-c1fe-402f-8673-925c82bbd2fb/small/abivax-logo-rgb-png.png https://www.parisdailyreporter.com/article/907389326-inventiva-strengthens-leadership-team-ahead-of-expected-phase-3-data-readout-of-lanifibranor Paris Daily Reporter en PressRelease 2026-04-22T20:00:00+00:00 Inventiva Strengthens Leadership Team Ahead of Expected Phase 3 Data Readout of Lanifibranor https://ml-eu.globenewswire.com/media/d96e203b-8941-46c7-888a-508900ab9a8b/small/logo-iva-jpg.jpg https://www.parisdailyreporter.com/article/907389682-inventiva-renforce-son-quipe-de-direction-l-approche-des-r-sultats-de-phase-3-du-lanifibranor Paris Daily Reporter en PressRelease 2026-04-22T20:00:00+00:00 Inventiva renforce son équipe de direction à l’approche des résultats de Phase 3 du lanifibranor https://ml-eu.globenewswire.com/media/d96e203b-8941-46c7-888a-508900ab9a8b/small/ https://www.parisdailyreporter.com/article/907348889-netris-pharma-nature-publishes-positive-pancreatic-cancer-phase-1b-data-for-np137-anti-netrin-1-monoclonal-antibody Paris Daily Reporter en PressRelease 2026-04-22T15:00:00+00:00 NETRIS Pharma: Nature publishes positive pancreatic cancer Phase 1b data for NP137 anti-netrin-1 monoclonal antibody https://ml-eu.globenewswire.com/media/dca1b4e9-d18b-4e3d-b301-c2b206e88591/small/netris-logo-jpg.jpg https://www.parisdailyreporter.com/article/907336127-ima-financial-group-places-4-billion-property-insurance-program-for-ai-data-center Paris Daily Reporter en PressRelease 2026-04-22T13:00:00+00:00 IMA Financial Group Places $4 Billion Property Insurance Program for AI Data Center https://ml.globenewswire.com/media/YjBhZjE4MmMtMDBiYS00MmJmLTg2ZDctZjBiNWI0OTJkNzcyLTUwMDE1MDkwMC0yMDI2LTA0LTIyLWVu/tiny/IMA-Financial-Group-Inc-.png https://www.parisdailyreporter.com/article/907321644-coave-therapeutics-to-present-two-posters-at-arvo-2026-on-first-in-class-ligand-conjugated-suprachoroidal-vector-and-lead-gene-therapy-program Paris Daily Reporter en PressRelease 2026-04-22T11:00:00+00:00 Coave Therapeutics to present two posters at ARVO 2026, on first-in-class ligand-conjugated suprachoroidal vector and lead gene therapy program https://ml-eu.globenewswire.com/media/b3d8ab3f-5292-4296-9ffa-7db27ba83e82/small/coave-tx-high-res-logo-1-png.png https://www.parisdailyreporter.com/article/907282228-elkedonia-strengthens-board-of-directors-with-appointment-of-pierre-d-epenoux-as-independent-chairman Paris Daily Reporter en PressRelease 2026-04-22T06:30:00+00:00 Elkedonia strengthens Board of Directors with appointment of Pierre d’Epenoux as Independent Chairman https://ml-eu.globenewswire.com/media/4eedea9c-804b-40ba-9a97-16f979ef7779/small/logo-elkedonia-png.png https://www.parisdailyreporter.com/article/907282233-elkedonia-renforce-son-comit-strat-gique-avec-la-nomination-de-pierre-d-epenoux-comme-pr-sident-ind-pendant Paris Daily Reporter en PressRelease 2026-04-22T06:30:00+00:00 Elkedonia renforce son Comité stratégique avec la nomination de Pierre d'Epenoux comme Président indépendant https://ml-eu.globenewswire.com/media/4eedea9c-804b-40ba-9a97-16f979ef7779/small/ https://www.parisdailyreporter.com/article/907269270-press-release-sanofi-s-tzield-approved-in-the-us-to-delay-the-onset-of-stage-3-type-1-diabetes-in-young-children Paris Daily Reporter en PressRelease 2026-04-22T05:05:00+00:00 Press Release: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://www.parisdailyreporter.com/article/907269585-communiqu-de-presse-tzield-de-sanofi-approuv-aux-tats-unis-pour-retarder-l-apparition-du-diab-te-de-type-1-de-stade-3-chez-les-jeunes-enfants Paris Daily Reporter en PressRelease 2026-04-22T05:05:00+00:00 Communiqué de presse : Tzield de Sanofi approuvé aux États-Unis pour retarder l’apparition du diabète de type 1 de stade 3 chez les jeunes enfants https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://www.parisdailyreporter.com/article/907268735-ojemda-approved-in-the-european-union-as-the-first-targeted-therapy-in-relapsed-or-refractory-pediatric-low-grade-glioma-regardless-of-braf Paris Daily Reporter en PressRelease 2026-04-22T05:00:00+00:00 Ojemda® approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of BRAF alteration https://ml-eu.globenewswire.com/media/81292fcc-6b3a-4e4a-a083-ea4191bf920a/small/ipsen-notified-website-1200x628pix-500kb-max-jpg.jpg https://www.parisdailyreporter.com/article/907268791-ojemda-approuv-dans-l-union-europ-enne-comme-premi-re-th-rapie-cibl-e-pour-les-enfants-atteints-de-gliome-p-diatrique-de-bas-grade-plgg-en Paris Daily Reporter en PressRelease 2026-04-22T05:00:00+00:00 Ojemda® approuvé dans l’Union européenne comme première thérapie ciblée pour les enfants atteints de gliome pédiatrique de bas grade (pLGG), en rechute ou réfractaire, indépendamment de l’altération de BRAF https://ml-eu.globenewswire.com/media/81292fcc-6b3a-4e4a-a083-ea4191bf920a/small/ https://www.parisdailyreporter.com/article/907268975-press-release-sanofi-provides-update-on-the-regulatory-submission-for-sarclisa-subcutaneous-in-the-us Paris Daily Reporter en PressRelease 2026-04-22T05:00:00+00:00 Press Release: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://www.parisdailyreporter.com/article/907269156-communiqu-de-presse-sanofi-fait-le-point-sur-la-soumission-r-glementaire-de-sarclisa-en-formulation-sous-cutan-e-aux-tats-unis Paris Daily Reporter en PressRelease 2026-04-22T05:00:00+00:00 Communiqué de presse : Sanofi fait le point sur la soumission réglementaire de Sarclisa en formulation sous-cutanée aux États-Unis https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://www.parisdailyreporter.com/article/907256405-team-elles-and-jelenew-partner-to-drive-women-s-cycling-community-in-loire-atlantique Paris Daily Reporter en PressRelease 2026-04-22T03:12:56+00:00 Team Elles and Jelenew Partner to Drive Women’s Cycling Community in Loire Atlantique https://ml-eu.globenewswire.com/media/14bc354f-6d6d-4f3d-9fe2-dd60e111cfa7/small/20250224-162924-png.png